Sign in
Taking people in United StatesPhase 2

Testing Obinutuzumab with Chemotherapy for Returning B-Cell Lymphoma in Young People

Tests obinutuzumab, alone and with chemotherapy, in young people with returning B-cell lymphoma.

Key facts

Who runs it
New York Medical College
Where
Valhalla, United StatesSee the site
Trial code
Registry title
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Status
Recruiting
Phase
Phase 2
People taking part
25 people, planned
Started
21 Aug 2015
Expected to end
Dec 2027
Type of study
Interventional, 2 groups
Treatments tested
  • Obinutuzumab
  • Liposomal ARA-C
  • Ifosfamide
  • Carboplatin
  • Etoposide
Record updated
23 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children, teenagers and young adults whose CD20-positive B-cell lymphoma has come back or did not respond to first treatment.

Age
From 3 to 31 years.
Sex
All sexes can join.
Disease stage
First relapse or no response to first treatment (primary induction failure) of CD20-positive B-cell lymphoma, such as diffuse large B-cell lymphoma, Burkitt lymphoma, primary mediastinal B-cell lymphoma, CD20+ B-lymphoblastic lymphoma or follicular lymphoma grade III.
Earlier treatment
No prior obinutuzumab (GA101). No chemotherapy that lowers blood counts within 2 weeks before entry. Waiting times after earlier radiation therapy apply. Steroids are allowed, but not started more than 7 days before treatment begins.
Biomarker or test result
The lymphoma must be CD20 positive.

Main reasons for not taking part

  • Newly diagnosed lymphoma that has not been treated before
  • Known inborn or acquired immune deficiency
  • Prior solid organ transplant
  • Allogeneic stem cell transplant within 60 days, or active severe graft-versus-host disease (grade 3 or higher)
  • Uncontrolled hepatitis B or C infection

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Patients in first relapse or primary induction failure CD20 positive B-cell leukemia/lymphoma including:; Diffuse Large B-Cell Lymphoma; Burkitt Lymphoma; High Grade B-cell Lymphoma: Not Otherwise Specified (NOS); Primary mediastinal B-cell lymphoma (PMBL); CD20+ B-lymphoblastic lymphoma; Follicular lymphoma, Grade III; Karnofsky ≥ 60% for patients > 16 years of age and; Lansky ≥ 60 for patients ≤ 16 years of age; Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study; Patients may not have received prior therapy with obinutuzumab (GA101); Radiation Therapy (XRT): Date of receiving prior XRT must be > 2 weeks for local palliative XRT (small port); > 6 months must have elapsed if prior craniospinal XRT or if > 50% radiation of pelvis; > 6 weeks must have elapsed if other substantial bone marrow radiation; Steroids: Patients may have received prior steroid treatment, but not started greater than 7 days prior to initiation of protocol therapy; Adequate organ function

Who cannot take part

  • Patients with newly diagnosed, previously untreated B-NHL
  • Prior solid organ transplantation
  • Prior allogeneic stem cell transplant within 60 days or active acute Graft-vs-Host-Disease (GVHD) grade 3 or higher
  • History of grade 4 anaphylactic reactions to humanized or murine monoclonal antibodies
  • Uncontrolled hepatitis B and/or C infection
  • Known congenital or acquired immune deficiency

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 3 and 31 years old?

Where in United States

  • New York Medical CollegeValhalla, United StatesContact: Jessica Hochberg, MDTaking people

About the trial

What the trial wants to find out

The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).

The 2 groups in the trial

  • Central Nervous System (CNS) NegativeTreatment being tested

    All patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2. Patients without CNS involvement will receive one dose of Liposomal cytarabine for CNS prophylaxis on day -13. Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting one day prior to the Liposomal cytarabine. Dexamethasone 0.15 mg/kg/dose (max 4mg) IV BID will be given days -14 to -10. Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE. O-ICE chemotherapy is given in 21-day (3-week) cycles. Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13. Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.

    Treatment: Obinutuzumab, Liposomal ARA-C, Ifosfamide, Carboplatin, and Etoposide

  • CNS PositiveTreatment being tested

    All patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2. Patients with positive CSF prior to enrollment will receive treatment with two doses of Liposomal cytarabine during the prephase portion of therapy. Liposomal cytarabine will be given intrathecally on days -13 and -5. Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting the day prior to the Liposomal cytarabine. Dexamethasone will be given days -14 to -10 and days -6 through -2. Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE. O-ICE chemotherapy is given in 21-day (3-week) cycles. Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13. Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.

    Treatment: Obinutuzumab, Liposomal ARA-C, Ifosfamide, Carboplatin, and Etoposide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Chemoimmunotherapy With Obinutuzumab, Ifosfamide, Carboplatin and Etoposide (O-ICE) in Children, Adolescents and Young Adults With Recurrent Refractory CD20+ Mature B-NHL
Plain-language title
Testing Obinutuzumab with Chemotherapy for Returning B-Cell Lymphoma in Young PeopleGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT02393157, who can take part
Record updated
23 October 2026